Viridian Therapeutics, Inc.(VRDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VRDN Viridian Therapeutics, Inc.

Trading 10-19 13:07:04 EDT

20.48

+1.45

+7.62%

High20.62	Low19.07	Vol1.05M
Open19.23	D1 Closing19.03	Amplitude8.15%
Mkt Cap2.32B	Tradable Cap2.07B	Total Shares113.29M
T/O21.07M	T/O Rate1.04%	Tradable Shares101.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VRDN","market":"US","secType":"STK","nameCN":"Viridian Therapeutics, Inc.","latestPrice":20.48,"timestamp":1792429622791,"preClose":19.03,"halted":0,"volume":1046391,"delay":0,"changeRate":0.07619548081975823,"floatShares":101000000,"shares":113292269,"eps":-3.45791,"marketStatus":"Trading","change":1.45,"latestTime":"10-19 13:07:04 EDT","open":19.23,"high":20.62,"low":19.07,"amount":21067727.708655,"amplitude":0.08145,"askPrice":20.5,"askSize":200,"bidPrice":20.47,"bidSize":6,"shortable":3,"etf":0,"ttmEps":-3.45791,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1792440000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":19.03,"preHourTrading":{"tag":"盘前","latestPrice":19.03,"preClose":19.03,"latestTime":"09:26 EDT","volume":253,"amount":4813.000148,"timestamp":1792416401772,"change":0,"changeRate":0,"amplitude":0.03731},"postHourTrading":{"tag":"盘后","latestPrice":19.05,"preClose":19.03,"latestTime":"19:30 EDT","volume":65579,"amount":1247972.16,"timestamp":1792193404993,"change":0.02,"changeRate":0.001051,"amplitude":0.001051},"volumeRatio":0.753028,"impliedVol":0.7161,"impliedVolPercentile":0.3705},"requestUrl":"/m/hq/s/VRDN","defaultTab":"news","newsList":[{"id":"2674882333","title":"RBC Capital Keeps Their Buy Rating on Viridian Therapeutics (VRDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674882333","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674882333?lang=en_us&edition=fundamental","pubTime":"2026-10-09 09:48","pubTimestamp":1791510481,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Lisa Walter from RBC Capital maintained a Buy rating on Viridian Therapeutics, with a price target of $38.00. Walte...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672742406","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2672742406","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672742406?lang=en_us&edition=fundamental","pubTime":"2026-10-03 09:50","pubTimestamp":1790992231,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insulet (PODD) and Viridian Therapeutics (VRDN) with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-369?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-369?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065169927.USD","XBI","HCSG","LABU","BK4082","BK4551","LU2065171311.SGD","LU2065170008.USD","LU1119994496.HKD","LU2324357040.USD","LU1084165304.USD","LU1261432733.SGD","BK4588","XLV","PODD","LU2065171402.SGD","BK4139","BK4566","BK4585","LU0128526141.USD","VRDN","BK4137","LU0728928796.USD","BK4581","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669072123","title":"Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2669072123","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669072123?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:45","pubTimestamp":1790091902,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics'  Lumvoa is off to a \"stronger start\" than anticipated, RBC Capital Markets said in a Tuesday note.RBC analysts talked with six key opinion leaders about the drug, which treats Thyroid Eye Disease, and discovered that it has had good early uptake so far. Half of the doctors have written at least one prescription for the drug since its launch on June 26, and a third have reported infusing at least one patient, the analysts noted.The evidence of early adoption suggests that physicians are enthusiastic about gaining experience with Lumvoa and seeing how it stacks up against competing treatment Tepezza on efficacy and safety, the analysts said.Rather than clinical reluctance, the main headwind for Lumvoa in the near term is challenges with access; a permanent J-code to avoid insurance delays still is to come and there have been formulary delays at academic centers, according to the note.RBC reiterated the company's stock rating at outperform, speculative risk, and rai","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","LENZ","BK4007","VRDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669149323","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (VRDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669149323","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669149323?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:10","pubTimestamp":1790075417,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-cvrx-cvrx-butterfly-network-bfly-and-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-cvrx-cvrx-butterfly-network-bfly-and-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4588","BFLY","BK4539","BK4585","LABU","XLV","BK4137","LU0029874061.USD","BK4139","BK4581","CVRX","LU0128526141.USD","VRDN","BK4082","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669102351","title":"Viridian Therapeutics, Inc. : RBC Raises Target Price to $38 from $36","url":"https://stock-news.laohu8.com/highlight/detail?id=2669102351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669102351?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:24","pubTimestamp":1790069041,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nFWN45E02I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607925","title":"Sling Therapeutics Raises $123 Million to Advance Thyroid Eye Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607925","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667607925?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:00","pubTimestamp":1789556400,"startTime":"0","endTime":"0","summary":"Sling Therapeutics raises $123 million to advance thyroid eye disease drugSept 16 (Reuters)-Drug developer Sling Therapeutics said on Wednesday ithad raised $123 million to advance a late-stage trial ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nL4N457178:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","LU0122379950.USD","LU1023059063.AUD","BK4581","IE0009355771.USD","LU2242646821.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD","BK4534","VRDN","PBE","LU2112291526.USD","AMGN","LU1571399168.USD","LU0109394709.USD","LU1057294990.SGD","LU2468319806.SGD","BIB","BK4588","LU1061106388.HKD","LU0058720904.USD","LU0289739699.SGD","LU2089984988.USD","BK4533","SG9999001440.SGD","IE0002141913.USD","PJP","LU0320765992.SGD","LU1983299246.USD","BK4566","IE00BFTCPJ56.SGD","BK4139","BK4599","IBB","TBXU","BK4585","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU2242652126.USD","IBBQ","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664846084","title":"Viridian Therapeutics Joins Wells Fargo Annual Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2664846084","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664846084?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:00","pubTimestamp":1788379255,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics joins Wells Fargo annual healthcare conference fireside chatViridian Therapeutics management will join a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8, 2026.Session is scheduled for 12:45 p.m. ET.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on September 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL6p97r2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664859516","title":"Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), Teladoc (TDOC) and Protagonist Therapeutics (PTGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664859516","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664859516?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:10","pubTimestamp":1788264606,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viridian Therapeutics (VRDN), Teladoc (TDOC) and P...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viridian-therapeutics-vrdn-teladoc-tdoc-and-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viridian-therapeutics-vrdn-teladoc-tdoc-and-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","PTGX","BK4167","BK4581","TDOC","BK4504","LU0128526141.USD","VRDN","BK4534","LU1861559042.SGD","LU0029874061.USD","HCSG","LU1861558580.USD","XLV","BK4137","XBI","BK4567","BK4139","BK4548","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661580502","title":"Viridian Therapeutics Chief Legal Officer Jennifer Tousignant Disposes of Common Shares Worth $348,194","url":"https://stock-news.laohu8.com/highlight/detail?id=2661580502","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661580502?lang=en_us&edition=fundamental","pubTime":"2026-08-21 08:05","pubTimestamp":1787270749,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics Chief Legal Officer Jennifer Tousignant disposes of common shares worth $348,194Jennifer Tousignant, chief legal officer at Viridian Therapeutics, sold 14,212 common shares at US","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL4KVgzK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Viridian Therapeutics Chief Legal Officer Jennifer Tousignant Disposes of Common Shares Worth $348,194","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660287027","title":"Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Viridian Therapeutics (VRDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660287027","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660287027?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:40","pubTimestamp":1787233213,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Health Catalyst (HCAT) and Viridian Therapeutics (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-health-catalyst-hcat-and-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-health-catalyst-hcat-and-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LU0128526141.USD","VRDN","LABU","HCSG","BK4585","HCAT","BK4139","XBI","BK4167","BK4581","LU0029874061.USD","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659187825","title":"Viridian Therapeutics (VRDN) Gets a Buy from Truist Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659187825","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659187825?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:26","pubTimestamp":1786587962,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Gregory Renza maintained a Buy rating on Viridian Therapeutics on August 11 and set a price target of $39.00. The company’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/viridian-therapeutics-vrdn-gets-a-buy-from-truist-financial-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/viridian-therapeutics-vrdn-gets-a-buy-from-truist-financial-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658781958","title":"Is Viridian Therapeutics' (VRDN) Widening Losses Despite Higher Revenue Reframing Its Risk Reward Profile?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658781958","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658781958?lang=en_us&edition=fundamental","pubTime":"2026-08-10 23:33","pubTimestamp":1786375995,"startTime":"0","endTime":"0","summary":"In the past, Viridian Therapeutics reported second-quarter 2026 results showing revenue of US$284,000 versus US$75,000 a year earlier, alongside a wider net loss of US$127.12 million and basic loss per share of US$1.05 from continuing operations.\nFor the first half of 2026, revenue rose to US$425,000 from US$147,000 while net loss increased to US$232.02 million and basic loss per share edged up to US$1.95, highlighting growing expenses outpacing early-stage revenue.\nNext, we will examine how...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/is-viridian-therapeutics-vrdn-widening-losses-despite-higher","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/is-viridian-therapeutics-vrdn-widening-losses-despite-higher","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658017939","title":"Viridian Therapeutics (VRDN) Receives a Buy from Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2658017939","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658017939?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:45","pubTimestamp":1786365941,"startTime":"0","endTime":"0","summary":"In a report released today, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Viridian Therapeutics, with a price target of $26.00. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/viridian-therapeutics-vrdn-receives-a-buy-from-evercore-isi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/viridian-therapeutics-vrdn-receives-a-buy-from-evercore-isi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657036652","title":"Viridian Therapeutics (VRDN) Receives a Buy from LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2657036652","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657036652?lang=en_us&edition=fundamental","pubTime":"2026-08-07 03:46","pubTimestamp":1786045561,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Viridian Therapeutics today and set a price target of $35.00. Katkhuda covers the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/viridian-therapeutics-vrdn-receives-a-buy-from-lifesci-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/viridian-therapeutics-vrdn-receives-a-buy-from-lifesci-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657637232","title":"Viridian Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657637232","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657637232?lang=en_us&edition=fundamental","pubTime":"2026-08-06 22:01","pubTimestamp":1786024893,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryViridian Therapeutics IncVRDN.OQreported a quarterly adjusted loss of $1.05 per share for the quarter ended Ju","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N44325D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657635318","title":"Viridian Therapeutics Q2 Net Loss Widens as Lumvoa Launch Lifts Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657635318","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657635318?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:36","pubTimestamp":1786016160,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics Q2 net loss widens as Lumvoa launch lifts costsOverviewU.S. biotech firm's Q2 net loss widened yr/yr as Lumvoa launch drove higher SG&A costsCompany ended Q2 with $981.5 mln in c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430IF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","BK4584","IBRN","VRDN","DNTH","OCUL","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638228","title":"Viridian Net Loss Widens to $127.12 Million in Q2 FY26; SG&A Expenses Climb to $54.98 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638228","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638228?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:12","pubTimestamp":1786014726,"startTime":"0","endTime":"0","summary":"Viridian net loss widens to $127.12 million in Q2 FY26; SG&A expenses climb to $54.98 millionViridian Therapeutics posted a GAAP net loss of $127.12 million, widening from $100.74 million a year earli","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL96j6dX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657668076","title":"Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657668076","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657668076?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:01","pubTimestamp":1786014060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUALDJJG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657567780","title":"Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657567780","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657567780?lang=en_us&edition=fundamental","pubTime":"2026-08-05 05:20","pubTimestamp":1785878408,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dianthus Therapeutics (DNTH) and Viridian Therapeuti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dianthus-therapeutics-dnth-and-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dianthus-therapeutics-dnth-and-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4581","VRDN","XLV","IBRN","XBI","LABU","BK4137","BK4585","HCSG","BK4588","LU0029874061.USD","DNTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655829617","title":"How Positive Elegrobart REVEAL-1 Phase III Data Could Impact Viridian Therapeutics (VRDN) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2655829617","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655829617?lang=en_us&edition=fundamental","pubTime":"2026-07-30 15:19","pubTimestamp":1785395970,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics recently reported positive topline results from its Elegrobart REVEAL-1 phase III trial in Graves' ophthalmopathy and outlined plans to submit a Biologics License Application in early 2027.\nThis progress, combined with the recent approval of Viridian’s LUMVOA and a pipeline that includes other emerging therapies for Graves’ ophthalmopathy, highlights the company’s growing role in this specialized autoimmune eye disease market.\nWe’ll now examine how the positive...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/how-positive-elegrobart-reveal-1-phase-iii-data-could-impact","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/how-positive-elegrobart-reveal-1-phase-iii-data-could-impact","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4134","III","BK4211","ISBC","VRDN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.viridiantherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":-0.152},{"period":"3month","weight":0.0555},{"period":"6month","weight":0.2858},{"period":"1year","weight":-0.173},{"period":"ytd","weight":-0.3885}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1193}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.269131},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.083186},{"month":3,"riseRate":0.25,"avgChangeRate":-0.101161},{"month":4,"riseRate":0.583333,"avgChangeRate":0.000279},{"month":5,"riseRate":0.333333,"avgChangeRate":0.008151},{"month":6,"riseRate":0.583333,"avgChangeRate":0.009034},{"month":7,"riseRate":0.538462,"avgChangeRate":0.011548},{"month":8,"riseRate":0.230769,"avgChangeRate":-0.059066},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.020088},{"month":10,"riseRate":0.230769,"avgChangeRate":-0.043767},{"month":11,"riseRate":0.583333,"avgChangeRate":0.157254},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.069844}],"exchange":"NASDAQ","name":"Viridian Therapeutics, Inc.","nameEN":"Viridian Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viridian Therapeutics, Inc.(VRDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Viridian Therapeutics, Inc.(VRDN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Viridian Therapeutics, Inc.,VRDN,Viridian Therapeutics, Inc.股票,Viridian Therapeutics, Inc.股票老虎,Viridian Therapeutics, Inc.股票老虎国际,Viridian Therapeutics, Inc.行情,Viridian Therapeutics, Inc.股票行情,Viridian Therapeutics, Inc.股价,Viridian Therapeutics, Inc.股市,Viridian Therapeutics, Inc.股票价格,Viridian Therapeutics, Inc.股票交易,Viridian Therapeutics, Inc.股票购买,Viridian Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viridian Therapeutics, Inc.(VRDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Viridian Therapeutics, Inc.(VRDN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}